

- P-1**      **Silencing of CD81 and Claudin-1 expression by small interfering RNAs inhibits HCV entry**  
Anirban MANDAL, Krishna Kumar GANTA, Binay CHAUBEY
- P-2**      **Identification and analysis of a novel important envelope region required for HCV infection**  
Noriyuki WATANABE, Nanako AIHARA, Tomoko DATE, Hussein H ALY, Hideki AIZAKI, Takaji WAKITA
- P-3**      **Monoclonal antibodies against the extracellular domains of occludin block hepatitis C virus infection in human liver chimeric mice**  
Masayoshi FUKASAWA, Yoshimi SHIMIZU, Yoshitaka SHIRASAGO, Tetsuro SUZUKI, Takaji WAKITA, Kentaro HANADA, Kiyohito YAGI, Masuo KONDOH
- P-4**      **CD81-independent HCV entry utilizing very-low-density lipoprotein receptor**  
Saneyuki UJINO, Hironori NISHITSUJI, Kunitada SHIMOTOHNO
- P-5**      **Vanitaracin A is a novel entry inhibitor of hepatitis B and D viruses through targeting NTCP**  
Manabu KANEKO, Koichi WATASHI, Shinji KAMISUKI, Masashi IWAMOTO, Senko TSUKUDA, Hirofumi OHASHI, Fumihiro KAWAI, Masashi MIZOKAMI, San-Yong PARK, Yasuhito TANAKA, Ryosuke SUZUKI, Hideki AIZAKI, Fumio SUGAWARA, Naoko OTANI, Takaji WAKITA
- P-6**      **Retinoid inhibitors abolish the host permissiveness to hepatitis B virus infection by modulating the expression of NTCP**  
Senko TSUKUDA, Koichi WATASHI, Masashi IWAMOTO, Ryosuke SUZUKI, Hideki AIZAKI, Soichi KOJIMA, Masaya SUGIYAMA, Yasuhito TANAKA, Masashi MIZOKAMI, Takaji WAKITA

- P-7** **ISG12 inhibits HCV replication through activation of the Jak/STAT signaling pathway**  
Yanzhao CHEN, Chen LIMIN
- P-8** **HIV-1 and HCV have comparable genetic and phenotypic protease quasispecies diversity**  
Miguel Angel MARTINEZ, Ana JORDAN-PAIZ, Maria NEVOT, Sandra FRANCO
- P-9** **Non-Stop mediated RNA decay mechanism regulates Hepatitis B virus replication**  
Hussein H. ALY, Koichi WATASHI, Kazuaki CHAYAMA, Takaji WAKITA
- P-10** **Exploring interactions between GBF1 and HCV proteins**  
Yves ROUILLE, Lucie GOUESLAIN, Najet LEBSIR, Rayan FARHAT, Francois PENIN, Jean DUBUISSON, Catherine L JACKSON
- P-11** **A role for phosphorylation in LCS I in regulating cellular interactions of HCV NS5A**  
Niluka GOONAWARDANE, Mark HARRIS
- P-12** **The complex relationship between NS5A hyperphosphorylation and genome replication: defining a role for residue 146**  
Niluka GOONAWARDANE, Mark HARRIS
- P-13** **Inositol polyphosphate-5-phosphatase F facilitates hepatitis C virus replication via upregulating autophagy**  
Yu-Hsuan WU, Ching-Kai TSENG, Kung-Chia YOUNG, Jing-Ching LEE
- P-14** **Regulation of Hepatitis C Virus by tRNA-derived Small Non-coding RNAs**  
Hee CHO, Wooseong LEE, Geon-Woo KIM, Jae-Su MOON, Jong-Won OH
- P-15** **The HCV cell culture system identified fungal-derived neoechinulin B as a novel antagonist of liver X receptor**  
Koichi WATASHI, Syo NAKAJIMA, Hirofumi OHASHI, Shinji KAMISUKI, Andrew Tae-Jun KWON, Harukazu SUZUKI, Senko TSUKUDA, Ryosuke SUZUKI, Hideki AIZAKI, Takanobu KATO, Fumio SUGAWARA, Takaji WAKITA
- P-16** **Variant fitness compensation in HCV by rescue of distinct NS3 protease functions and innate immune escape mechanisms**  
Georg DULTZ, Tetsuro SHIMAKAMI, Murai KAZUHISA, Iris ANTES, Stefan ZEUZEM, Robert TAMPÉ, Stanley M LEMON, Christoph WELSCH
- P-17** **Yellow Fever virus genome-derived small RNA reduces T cell activation and enhances viral replication by targeting the PTPRE phosphatase**  
Jack T STAPLETON, James H MCLINDEN, Nirjal BHATTARAI, Qing CHANG, Thomas M KAUFMAN, Suzanne L CASSEL, Fayyaz S SUTTERWALA, Hillel HAIM, Donna KLINZMAN, Jinhua XIANG
- P-18** **Using proteomics to identify novel host proteins regulating Hepatitis C Virus infection**  
Holly RAMAGE, Renuka KUMAR, Nevan KROGAN, Melanie OTT

- P-19**      **Differential hepatitis C virus RNA target site selection and host factor activities of naturally-occurring miR-122 3' variants**  
Daisuke YAMANE, Sara R SELITSKY, Tetsuro SHIMAKAMI, You LI, Masao HONDA, Michinori KOHARA, Praveen SETHUPATHY, Stanley M LEMON
- P-20**      **Annexins participate in the HCV RNA replication**  
Takayuki ABE, Ikuo SHOJI, Yoshiharu MATSUURA
- P-21**      **Cooperative stimulation of Hepatitis C Virus RNA translation by microRNA-122/Argonaute 2 complexes**  
Michael NIEPMANN, Anika NIEDER-RÖHRMANN, Nadia DÜNNES, Gesche K GERRESHEIM, Lyudmila A SHALAMOVA
- P-22**      **In Vitro Selection of Simeprevir-resistance Mutants for Hepatitis C Virus with NS3-Q80K Polymorphism in Genotype 1a**  
Tetsuro SHIMAKAMI, Kazuhisa MURAI, Christoph WELSCH, Takayoshi SHIRASAKI, Masao HONDA, Shuichi KANEKO
- P-23**      **Identification essential host factors for hepatitis C virus infection by a high-throughput CRISPR-Cas9 screening strategy**  
Wei YANG, Yuqiang NIU, Min CHENG, Youhui SI, Xiaojing CHI, Xiuying LIU
- P-24**      **INTRACELLULAR PROTECTION OF HSPB8 PROTEIN IN HCV INFECTIONS**  
Paula RAHAL, Ana Claudia S BRAGA, Mariana N BATISTA, Mônica M AKINAGA, Bruno M CARNEIRO
- P-25**      **Cell Culture-Adaptive Mutations of NS5A Affect Replication of Hepatitis C Virus Differentially Depending on the Viral Genotypes**  
Seungtaek KIM, Aeri CHUNG, Bora JIN, Kwang-Hyub HAN, Sang Hoon AHN
- P-26**      **Prevalence of HCV and First report of complete genome sequence of HCV among the general population in Cambodia**  
Chikako YAMAMOTO, Shintaro NAGASHIMA, Somana SVAY, Sirany HOK, Son Huy DO, Channarena CHUON, Hiroko FUJII, Mayumi FUJIMOTO, Shiho SAITO, Muzembo Basilua ANDRE, Keiko KATAYAMA, Kazuaki TAKAHASHI, Junko TANAKA
- P-27**      **Vit B12 decreases HCV replication in replicon cell lines**  
Jee-Fu HUANG, Chia-Yen DAI, Ming-Lung YU, Wan-Long CHUANG
- P-28**      **Hepatitis B virus capsid formation is regulated by microtubules and their posttranslational modification**  
Masashi IWAMOTO, Masaya SUGIYAMA, Ryosuke SUZUKI, Hideki AIZAKI, Yasuhito TANAKA, Masashi MIZOKAMI, Naoko OHTANI, Takaji WAKITA, Koichi WATASHI
- P-29**      **DNA-PKcs and Rad18 are required for HCV replication**  
Yasuo ARIUMI, Satoshi TATEISHI, Takaji WAKITA, Nobuyuki KATO
- P-30**      **The mechanisms of epigenetic regulation on hypericin inhibiting HCV replication**  
Chao-ming SHIH, Chih-hsien WU, Jiunn-liang KO

- P-31**      **Pathogenic contribution of Macrophage migration Inhibitory Factor (MIF) during Hepatitis C virus (HCV) infection**  
Ching Wooen SZE, Wei Kiang LIM, Victor C YU, Yee-Joo TAN
- P-32**      **Adaptation of previously developed infectious clones of hepatitis C virus genotypes 1 and 2 to Huh7 cells**  
Yiping LI, Fuxiang ZHENG, Liang RONG, Jiemin SHEN, Yetong FENG
- P-33**      **The role of autophagy in the formation of double membrane vesicles in HCV-infected cells**  
Keisuke TABATA, David PAUL, Ralf BARTENSCHLAGER
- P-34**      **Amino acid substitutions in IFN sensitivity-determining region of HCV-NS5A affect infectious virus production and ISG induction**  
Ryuichi SUGIYAMA, Nao SUGIYAMA, Asako MURAYAMA, Megumi TASAKA-FUJITA, Norie YAMADA, Sayuri NITTA, Takahiro MASAKI, Koji ISHII, Akihide RYO, Takaji WAKITA, Takanobu KATO

- P-35**      **Rab32 is an essential host factor for hepatitis C virus particle assembly**  
Soon B HWANG, Tu M. PHAM, Yun-Sook LIM
- P-36**      **Neglected but Important Role of Apolipoprotein E Exchange in Hepatitis C Virus Infection**  
Gang LONG, Zaili YANG, Xiaoning WANG, Xiumei CHI, Fanfan ZHAO, Jinxu GUO, Pengjuan MA, Jin ZHONG, Junqi NIU, Xiaoyu PAN
- P-37**      **Quantitative Lipid Droplet Proteome Analysis Identifies Annexin A3 as a Cofactor for Hepatitis C Virus Particle Production**  
Eva HERKER, Kathrin ROESCH, Marcel KWIATKOWSKI, Sarah HOFMANN, Anja SCHOEBEL, Cordula GRUETTNER, Marcus WURLITZER, Hartmut SCHLUETER
- P-38**      **NF-  $\kappa$  B-inducing kinase (NIK) activates IKK-  $\alpha$  in regulation of hepatic lipogenesis and hepatitis C virus assembly**  
Qisheng LI, Brianna LOWEY, Stephan CHIU, Fang ZHANG, Kristin VALDEZ, T Jake LIANG
- P-39**      **Influence of apolipoprotein E on hepatitis C virus envelope proteins folding**  
Julie DRENEAU, Anne BULL, Elodie BEAUMONT, Philippe ROINGEARD, Audrey BOYER, Jean-Christophe MEUNIER
- P-40**      **Critical Role of the Basic Residue Clusters within Domain-I of HCV Core in Interaction with Viral Genome and Particles assembly**  
Guoli SHI, Mami MATSUDA, Ryosuke SUZUKI, Takaji WAKITA, Tetsuro SUZUKI
- P-41**      **Host Glycometabolism Modulates Hepatitis C Virus Release**  
Tao YU, Jin ZHONG
- P-42**      **Cell-death-inducing DFFA-like Effector B Contributes to the Assembly of Hepatitis C Virus (HCV) Particles and Interacts with HCV NS5A**  
Hua CAI, Wenxia YAO, Leike LI, Xinlei LI, Longbo HU, Runming MAI, Tao PENG

- P-43**      **The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection**  
Chen JIZHENG, Wang QIAN, Chen XINWEN
- P-44**      **Critical role of CREBH activation induced in HCV-infected cells in enhancing profibrogenic responses in nearby hepatic stellate cells**  
Takeshi CHIDA, Masahiko ITO, Kenji NAKASHIMA, Tetsuro SUZUKI
- P-45**      **Hepatitis C virus-induced inflammasome regulates lipid metabolism**  
Gulam WARIS, Steven MCRAE, Jawed IQBAL, Mehuli SARKAR-DUTTA, Samantha LANE, Abhiram NAGARAJ, Naushad ALI
- P-46**      **Pilot analysis reveals SPINK1 as an imminent diagnostic marker for Hepatitis B and C-associated Hepatocellular Carcinoma observed in Indonesian patients**  
Siti Eriaty Nur RUSLAN, Juniastuti, Bagaswoto Poedjo MARTONO, Nihayatus SA'ADAH, Mochamad AMIN, Soetjipto, Maria Inge LUSIDA
- P-47**      **Upregulation of MAPK phosphatase 3 is involved in HCV-induced dephosphorylation of FoxO1**  
Lin DENG, Ming CHEN, Ikuo SHOJI, Hak HOTTA
- P-48**      **Human hepatic stellate cells are permissive for hepatitis C virus infection/replication and play important roles in fibrosis**  
Takuma ZAITSU, Haruyo AOYAGI, Mami MATSUDA, Noriyuki WATANABE, Akira FUJIMOTO, Koichi WATASHI, Ryosuke SUZUKI, Takasuke FUKUHARA, Yoshiharu MATSUURA, Kenjiro WAKE, Tetsuro SUZUKI, Tomokazu MATSUURA, Koji TAMURA, Takaji WAKITA, Hideki AIZAKI
- P-49**      **Analysis of cellular factors involved in the particle formation and secretion of hepatitis C virus**  
Kenichi MORIKAWA, Goki SUDA, Jerome GOUITTENOIRE, Darius MORADPOUR, Naoya SAKAMOTO
- P-50**      **HCV-protein expression exacerbate hepatic pathogenesis induced by PTEN loss, through enhanced liver inflammation**  
Herve LERAT, Marion MERCEY, Mohamed-Rabah IMACHE, Natael SOREL, Jacqueline POLYTE, Aurore GAUDIN, Matteo MONTANI, Jean-Francois DUFOUR, Jean-Michel PAWLITSKY
- P-51**      **Analysis of viral variant spectra provides evidence for early in utero transmission of hepatitis C virus from mother to child**  
Virginie CALDERON, Ariane LAROUCHE, Sébastien FAUTEUX-DANIEL, Marc BOUCHER, Normand LAPOINTE, Fatima KAKKAR, Isabelle BOUCOIRAN, Armelle LE CAMPION, Hugo SOUDEYNS
- P-52**      **Lipid Metabolism in Relation to Development of Steatosis in Hepatitis C Virus Infected Hepatocyte-like Cells**  
Wilson TAT, Rineke STEENBERGEN, D. Lorne TYRRELL
- P-53**      **Amelioration of HCV liver fibrosis by selective inhibitor of Wnt/  $\beta$  -catenin/CBP signaling**  
Michinori KOHARA, Yuko TOKUNAGA, Yosuke OSAWA, Takahiro OHTSUKI, Kenzaburo YAMAJI, Daisuke YAMANE, Keisuke MUNEKATA, Mitsuko HARA, Soichi KOJIMA, Kiminori KIMURA

- P-54**      **Molecular mechanism of HCV-induced lysosomal degradation of HNF-1  $\alpha$  protein**  
Chieko MATSUI, Nanae MINAMI, Lin DENG, Ikuo SHOJI
- P-55**      **From Acute to Chronic Stages of Hepatitis C Virus Infections in Cultivated Reporter Cells**  
Tsai PEIJU, Cheng HSIANG-LIN, Young KUNG-CHIA
- P-56**      **Overexpressed protein kinase R (PKR) in hepatocellular carcinoma with HCV infection modulates DNA methylation**  
Takao WATANABE, Yoshio TOKUMOTO, Masashi HIROOKA, Osamu YOSHIDA, Yohei KOIZUMI, Yusuke IMAI, Yoshiko NAKAMURA, Masanori ABE, Yoichi HIASA
- P-57**      **HEPATITIS C VIRUS CORE PROTEIN OF GENOTYPE 3a DOWNREGULATES PTEN EXPRESSION IN HEPATOCYTES THROUGH MICRORNAs-DEPENDENT MECHANISMS**  
Sophie CLÉMENT, Cyril SOBOLEWSKI, Stéphanie CONZELMANN, Francesco NEGRO, Michelangelo FOTI
- P-58**      **Regulation of Bcl-2 family proteins in cells infected with Flaviviruses**  
Toru OKAMOTO, Tatsuya SUZUKI, Shinji KUSAKABE, Junki HIRANO, Makoto TOKUNAGA, Takasuke FUKUHARA, Yoshiharu MATSUURA
- P-59**      **Deregulation of Wnt-beta-catenin signaling by hepatitis C virus infection-induced selective degradations of Dishevelled family proteins**  
Po-Yuan KE, Chih-Wei CHANG
- P-60**      **Hepatitis C virus targets the microRNA-induced silencing complex and attenuates host cellular microRNA functions**  
Takahiro MASAKI, Takanobu KATO, Yoshihiro MEZAKI, Mariko NAKAMURA, Tomokazu MATSUURA, Takaji WAKITA
- P-61**      **Functional studies of Hepatitis C core+1/ARFP protein**  
Savvina MOUSTAFA, Ioannis KARAKASILIOTIS, Niki VASSILAKI, Katerina KASSELLA, Sevi FRAKOLAKI, Penelope MAVROMARA
- P-62**      **Hepatitis viruses induce spread of liver cancer cells through generation of invadopodia**  
Liat NINIO, Avraham NISANI, Ateret DAVIDOVICH, Joel ALTER, Hava GIL-HENN, Meital GAL-TANAMY
- P-63**      **Adenylate kinase 4 modulates drug sensitivity and mitochondrial activity in HeLa cells**  
Koichi FUJISAWA, Taro TAKAMI, Toshihiko MATSUMOTO, Naoki YAMAMOTO, Isao SAKAIDA
- P-64**      **Cytotoxic Function of Bystander Activated CD8<sup>+</sup> T Cells is Associated with Liver Injury in Acute Hepatitis A**  
Eui-Cheol SHIN, Jihye KIM, Dong-Yeop CHANG, Hyun Woong LEE, Hyung Joon KIM

- P-65**      **The detection of iron metabolism related gene with the liver by NASH model rat**  
Teruhisa HIGUCHI, Akiko HUKUSHIMA, Kazushige NIREI, Hiroshi MATSUMURA, Mitsuhiro MORIYAMA
- P-66**      **Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing**  
Michio IMAMURA, Hiromi KAN, Nobuhiko HIRAGA, Takuro UCHIDA, Hiromi KAN, Hiromi ABE, Hiroshi AIKATA, Hidenori OCHI, C. Nelson HAYES, Kazuaki CHAYAMA
- P-67**      **Modulation of metabolic pathways by miR-124 during HCV infection**  
Tyler SHAW, Megan POWDRILL, Dennis ÖZCELIK, Curtis QUAN, Ragunath SINGARAVELU, John P PEZACKI
- P-68**      **Hepatitis C virus core protein interacts with Bnip3 and suppresses its dimerization and binding with LC3**  
Takeya TSUTSUMI, Akira KADO, Kazuya OKUSHIN, Kenichiro ENOOKU, Hidetaka FUJINAGA, Kyoji MORIYA, Hiroshi YOTSUYANAGI, Yumi KANEGAE, Izumu SAITO, Yoshiharu MATSUURA, Kazuhiko KOIKE
- P-69**      **Mutation in the promoter region of pre-S1 is associated with reduced disease activity of hepatitis B virus infection**  
Kazushi SUGIMOTO, Suguru OGURA, Norihiko YAMAMOTO, Motoh IWASA, Yoshiyuki TAKEI
- P-70**      **Mapping the region responsible for disease progression in the HBV preS1/S2 genome by deep sequencing**  
Yuichiro SUZUKI, Shinya MAEKAWA, Mitsuaki SATO, Masaru MURAOKA, Shuya MATSUDA, Natsuko NAKAKUKI, Yasuhiro NAKAYAMA, Taisuke INOUE, Minoru SAKAMOTO, Nobuyuki ENOMOTO



- P-71**      **Reactivation of hepatitis B virus during successful treatment of hepatitis C virus with interferon-free direct-acting antiviral**  
Masaaki KORENAGA, Keiko KORENAGA, Tatsuya KANTO, Masashi MIZOKAMI
- P-72**      **Analysis of glypican-3 as a predictive marker for postoperative recurrence of HCV related hepatocellular carcinoma**  
Kazuya OFUJI, Keigo SAITO, Hidetaka MATSUDA, Masahiro OHTANI, Katsushi HIRAMATSU, Tomoyuki NEMOTO, Yasunari NAKAMOTO, Tetsuya NAKATSURA
- P-73**      **Phylogenetic and phylodynamic analysis of hepatitis C virus genotype 1a in Okinawa, Japan**  
Kunikazu HOSHINO, Masaya SUGIYAMA, Tatsuji MAESHIRO, Tomoko DATE, Hirotaka SHOJI, Yohei MANO, Hiroyoshi DOI, Sachiyo YOSHIO, Tatsuya KANTO, Masashi MIZOKAMI
- P-74**      **Comparison of patient characteristics and survival between elderly and younger patients with hepatocellular carcinoma related to hepatitis C virus infection**  
Tomoyuki NEMOTO, Hidetaka MATSUDA, Masahiro OHTANI, Katsushi HIRAMATSU, Yasunari NAKAMOTO
- P-75**      **The impacts of Zepatier or Harvoni treatment on plasma lipid profiles in chronic hepatitis C patients**  
Chiung-Ying TSENG, Hung-Yu SUN, Wei-Jen TSAI, Pin-Nan CHENG, Yen-Cheng CHIU, Ting-Tsung CHANG, Kung-Chia YOUNG
- P-76**      **Efficacy and side effects of sofosbuvir and ribavirin in patients with hepatitis C virus genotype 2 infection**  
Sayuri NOMURA, Naoto KAWABE, Tomoki TAKAMURA, Takamitsu KURASHITA, Yuka OCHI, Masashi OHKI, Kazunori NAKAOKA, Toshiki KAN, Takuji NAKANO, Michihito MURAO, Senju HASHIMOTO, Kentaro YOSHIOKA
- P-77**      **Daclatasvir/Asunaprevir treatment increases albumin levels**  
Toshiki KAN, Naoto KAWABE, Sayuri NOMURA, Tomoki TAKAMURA, Takamitsu KURASHITA, Yuka OCHI, Masashi OHKI, Kazunori NAKAOKA, Takuji NAKANO, Michihito MURAO, Senju HASHIMOTO, Kentaro YOSHIOKA
- P-78**      **The influence of serum fatty acid profile and the effect of ezetimibe combination on simeprevir with peg-interferon/ribavirin therapy**  
Takao WATANABE, Yoshio TOKUMOTO, Masashi HIROOKA, Osamu YOSHIDA, Yohei KOIZUMI, Yusuke IMAI, Yoshiko NAKAMURA, Masanori ABE, Yoichi HIASA
- P-79**      **Interferon lambda 4 (IFNL4) CC host genetic variant is linked with spontaneous HCV clearance for genotypes 1, 2, and 3**  
Anders WIDELL, Marianne ALANKO-BLOMÉ, Vilma MOLNEGREN, Per BJÖRKMAN, Kristina NYSTRÖM, Martin LAGGING
- P-80**      **A multicenter observational study evaluating the antiviral efficacy and safety with chronic hepatitis C receiving asunaprevir/daclatasvir therapy**  
Yoshio TOKUMOTO, Takao WATANABE, Koji JOKO, Kojiro MICHITAKA, Yoshiyasu KISAKA, Norio HORIIKE, Seiji NAKANISHI, Yoshinori TANAKA, Yoshiko NAKAMURA, Yusuke IMAI, Yohei KOIZUMI, Osamu YOSHIDA, Masashi HIROOKA, Masanori ABE, Yoichi HIASA

- P-81**      **The effect of direct-acting antiviral therapy for patients with hepatitis C virus and hepatitis B virus coinfection**  
Kazuhiko HAYASHI, Masatoshi ISHIGAMI, Yoji ISHIZU, Teiji KUZUYA, Takashi HONDA, Isao NAKANO, Yoshiki HIROOKA, Hidemi GOTO
- P-82**      **Analysis of Hepatitis C Virus NS3 and NS5A Resistance Mutations after Daclatasvir plus Asunaprevir Treatment Failures in Korea**  
Seungtaek KIM, Hye-Jung PARK, Hye Won LEE, Kwang-Hyub HAN, Sang Hoon AHN
- P-83**      **Combination Therapy with Peginterferon and Entecavir for Persistent Viral Suppression in Patients with Chronic Hepatitis B**  
Satoru HAGIWARA, Naoshi NISHIDA, Masatoshi KUDO
- P-84**      **The Experience of Daclatasvir and Asunaprevir Treatment in Korean Patients with Genotype 1b Hepatitis C Virus Infection**  
Seungtaek KIM, Hye Won LEE, Beom Kyung KIM, Seung Up KIM, Jun Yong PARK, Do Young KIM, Kwang-Hyub HAN, Sang Hoon AHN
- P-85**      **Clinicopathological Characteristics of Steatohepatic Hepatocellular Carcinoma**  
Makiko TANAI, Etsuko HASHIMOTO, Kazuhisa KODAMA, Tomomi KOGISO, Katsutoshi TOKUSHIGE
- P-86**      **Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative anti-viral therapy**  
Huang CHUNG-FENG, Dai CHIA-YEN, Huang JEE-FU, Chuang WAN-LONG, Yu MING-LUNG
- P-87**      **A detailed hepatitis viral marker study in 3843 hepatocellular carcinoma patients From Taiwan Liver Cancer Network**  
Shiu-Feng HUANG, Il-Chi CHANG, Pei-Jer CHEN, Chi-Lin CHEN, Tseng-Chang YEN, Yu-Fan LIAW
- P-88**      **Anti-HDGF (hepatoma-derived growth factor) treatment as a possible new therapy for hepatocellular carcinoma**  
Hirayuki ENOMOTO, Hideji NAKAMURA, Hiroki NISHIKAWA, Ryo TAKATA, Kazunori YOH, Kunihiro HASEGAWA, Yukihisa YURI, Akio ISHII, Tomoyuki TAKASHIMA, Yoshiyuki SAKAI, Nobuhiro AIZAWA, Naoto IKEDA, Yoshinori IWATA, Hiroko IJIMA, Shuhei NISHIGUCHI
- P-89**      **Analysis of Dynamic Change in Serum Low Density Lipoprotein-Cholesterol Level during Hepatitis C Interferon-free Treatment**  
Satoru HASHIMOTO, Kohei HAYASHI, Yuki KUGIYAMA, Shigemune BEKKI, Shinjiro UCHIDA, Akira SAEKI, Shinya NAGAOKA, Seigo ABIRU, Kazumi YAMASAKI, Atsumasa KOMORI, Hiroshi YATSUHASHI
- P-90**      **Impact of inter-individual difference of CYP3A activity in DAA treatments**  
Tadashi IKEGAMI, Akira HONDA, Shoichiro YARA, Naoki KONISHI, Masashi MURAKAMI, Tadakuni MONMA, Takeshi HIRAYAMA, Junichi IWAMOTO, Teruo MIYAZAKI, Yasushi MATSUZAKI
- P-91**      **Selection of direct-acting antiviral treatment for achieving a sustained viral response**  
Ayumi SUGIURA, Satoru JOSHITA, Tomoo YAMAZAKI, Naoyuki FUJIMORI, Soichiro SHIBATA, Yuki ICHIKAWA, Michiharu KOMATSU, Akihiro MATSUMOTO, Takeji UMEMURA, Eiji TANAKA

- P-92**      **Liver Stiffness-Spleen Size-to-Platelet Ratio Risk Score Identifies Esophageal Varices in Chronic Liver Disease**  
Satoru JOSHITA, Soichiro SHIBATA, Takeji UMEMURA, Ayumi SUGIURA, Tomoo YAMAZAKI, Naoyuki FUJIMORI, Yuki ICHIKAWA, Michiharu KOMATSU, Akihiro MATSUMOTO, Eiji TANAKA
- P-93**      **Controlled attenuation parameter for the diagnosis of steatosis in chronic hepatitis C**  
Naoto KAWABE, Naohiro ICHINO, Senju HASHIMOTO, Michihito MURAO, Takuji NAKANO, Toshiki KAN, Kazunori NAKAOKA, Masashi OHKI, Yuka OCHI, Tomoki TAKAMURA, Sayuri NOMURA, Aiko FUKUI, Toru NISHIKAWA, Keisuke OSAKABE, Kentaro YOSHIOKA
- P-94**      **Therapeutic effect of direct-acting antivirals on hepatitis C virus reinfection after liver transplantation**  
Satoshi MIUMA, Hisamitsu MIYAAKI, Ryu SASAKI, Yuri MIYAZOE, Shinobu YAMAMICHI, Mio YAMASHIMA, Suguru NAKASHIKI, Tomohiro SUEHIRO, Hidetaka SHIBATA, Naota TAURA, Kazuhiko NAKAO
- P-95**      **Autotaxin is a novel marker for liver fibrosis in patients with chronic hepatitis C**  
Tomoo YAMAZAKI, Satoru JOSHITA, Takeji UMEMURA, Yoko USAMI, Naoyuki FUJIMORI, Ayumi SUGIURA, Soichiro SHIBATA, Yuki ICHIKAWA, Michiharu KOMATSU, Akihiro MATSUMOTO, Eiji TANAKA
- P-96**      **Serum ADAMTS 13 antigen level is associated with the risk of hepatocellular carcinoma in Japanese patients with hepatitis C virus**  
Kazumi YAMASAKI, Hitoshi IKEDA, Shigemune BEKKI, Yuki KUGIYAMA, Shinjiro UCHIDA, Satoru HASHIMOTO, Akira SAEKI, Shinya NAGAOKA, Seigo ABIRU, Atsumasa KOMORI, Hiroshi YATSUHASHI
- P-97**      **Tolerability of sofosbuvir-based therapy for aged patients with chronic hepatitis C**  
Ryotaro SAKAMORI, Tomohide TATSUMI, Takayuki YAKUSHIJIN, Ryoko YAMADA, Naoki MORISHITA, Yuki TAHATA, Ayako URABE, Kunimaro FURUTA, Hayato HIKITA, Hideki HAGIWARA, Naoki HIRAMATSU, Yukinori YAMADA, Yasuharu IMAI, Norio HAYASHI, Tetsuo TAKEHARA
- P-98**      **Resistance-associated variants during retreatment with daclatasvir/asunaprevir following the failure of simeprevir-based triple therapy among the patients with chronic hepatitis C**  
Ryotaro SAKAMORI, Tomohide TATSUMI, Takayuki YAKUSHIJIN, Ryoko YAMADA, Naoki MORISHITA, Yuki TAHATA, Ayako URABE, Kunimaro FURUTA, Hayato HIKITA, Atsushi HOSUI, Naoki HIRAMATSU, Eiji MITA, Shinji TAMURA, Yasuharu IMAI, Tetsuo TAKEHARA
- P-99**      **Addition of Ribavirin to Daclatasvir Plus Asunaprevir for Chronic Hepatitis C 1b Patients with Baseline NS5A Resistance-Associated Variants Improving Response Rate**  
Pei-Jer CHEN, Chun-Ming HONG, Chun-Jen LIU, Shiou-Hwei YEH
- P-100**      **To investigate the therapeutic strategy of huge hepatocellular carcinoma ( $\geq 10$ cm); the comparison between the surgical and the non-surgical treatment**  
Norihiko YAMAMOTO, Kazushi SUGIMOTO, Yasuaki TAMAI, Kyoko YOSHIKAWA, Suguru OGURA, Rumi MOROOKA, Ryosuke SUGIMOTO, Hideaki TANAKA, Hiroshi HASEGAWA, Motoh IWASA, Yoshiyuki TAKEI

- P-101**      **Polymorphism in the inosine triphosphatase gene influences the reduction of hemoglobin levels and ribavirin dose during sofosbuvir and ribavirin therapy**  
Ritsuzo KOZUKA, Akihiro TAMORI, Hoang HAI, Yuga TERANISHI, Hiroyuki MOTOYAMA, Etsushi KAWAMURA, Atsushi HAGIHARA, Sawako UCHIDA-KOBAYASHI, Hiroyasu MORIKAWA, Masaru ENOMOTO, Yoshiki MURAKAMI, Norifumi KAWADA
- P-102**      **Recurrence of hepatocellular carcinoma after hepatitis C virus eradication with all-oral regimens in patients who underwent curative treatments**  
Ryo NAKAGOMI, Ryosuke TATEISHI, Taijiro WAKE, Mizuki NISHIBATAKE, Naoto FUJIWARA, Masaya SATO, Tatsuya MINAMI, Kenichiro ENOOKU, Hayato NAKAGAWA, Yoshinari ASAOKA, Yuji KONDO, Kazuhiko KOIKE
- P-103**      **The usefulness of frequency analysis of Hepatitis C virus drug-resistant mutation and selecting DAAs in consideration of resistant mutation**  
Isao HIDAKA, Isao SAKAIDA
- P-104**      **Resistant-associated variants associated with failure of dual oral therapy with Daclatasvir and Asunaprevir**  
Seiichi MAWATARI, Akihiro MORIUCHI, Oki TANIYAMA, Haruka SAKAE, Sho IJUIN, Kazuaki TABU, Kohei ODA, Tsutomu TAMAI, Akio IDO
- P-105**      **Efficacy of dual oral therapy with asunaprevir and daclatasvir for elderly patients with hepatitis C**  
Takashi HONDA, Masatoshi ISHIGAMI, Yoji ISHIZU, Teiji KUZUYA, Kazuhiko HAYASHI, Yoshiki HIROOKA, Tetsuya ISHIKAWA, Hidemi GOTO
- P-106**      **Hepatitis C virus eradication by daclatasvir and asunaprevir therapy contributes to rapid changes in circulating lipid/lipoprotein and apolipoprotein profiles**  
Takeshi CHIDA, Maho NAGASAWA, Erika MATSUNAGA, Jun ITO, Kazuyoshi OHTA, Shin SHIMOYAMA, Satoru YAMAZAKI, Hidenao NORITAKE, Kazuhito KAWATA, Tetsuro SUZUKI, Yoshimasa KOBAYASHI
- P-107**      **The efficacy of phlebotomy treatment in patient with chronic hepatitis C**  
Shoichi SASAKI, Kazushige NIREI, Hiroshi MATSUMURA, Hitomi NAKAMURA, Shunichi MATSUOKA, Mitsuhiko MORIYAMA
- P-108**      **“Othello Hypothesis” Involved in the Development of Virologic Failure in Patients with Genotype 1b HCV Showing No-RAVs**  
Yoshihito UCHIDA, Jun-ichi KOUYAMA, Kayoko NAIKI, Kayoko SUGAWARA, Yukinori IMAI, Nobuaki NAKAYAMA, Satoshi MOCHIDA
- P-109**      **The role of alcohol metabolism-related SNP in the progression of liver disease in the HCV-patients achieving viral clearance**  
Shinya MAEKAWA, Natsuko NAKAKUKI, Mitsuki SATO, Yuichiro SUZUKI, Masaru MURAOKA, Shuya MATSUDA, Yasuhiro NAKAYAMA, Taisuke INOUE, Minoru SAKAMOTO, Nobuyuki ENOMOTO

- P-110 Stagnation of histological improvement is a predictor of development of hepatocellular carcinoma after hepatitis C virus eradication**  
Hiroyuki MOTOYAMA, Akihiro TAMORI, Sawako UCHIDA, Yuga TERANISHI, Ritsuzou KOTSUKA, Etsushi KAWAMURA, Jyunji HAGIHARA, Hiroyasu MORIKAWA, Yoshiki MURAKAMI, Masaru ENOMOTO, Norifumi KAWADA
- P-111 The efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C**  
Satoshi YAMAGIWA, Toru ISHIKAWA, Nobuo WAGURI, Soichi SUGITANI, Kenya KAMIMURA, Atsunori TSUCHIYA, Masaaki TAKAMURA, Hirokazu KAWAI, Shuji TERAI
- P-112 Prevalence of non-primate hepacivirus in horses in Mongolia**  
Tomoko DATE, Masaya SUGIYAMA, Damdindorj LKHAGVASUREN, Tsendsuren OYUNSUREN, Takaji WAKITA, Masashi MIZOKAMI
- P-113 The role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma**  
Asahiro MORISHITA, Hisakazu IWAMA, Koji FUJITA, Teppei SAKAMOTO, Takako NOMURA, Joji TANI, Hirohito YONEYAMA, Tsutomu MASAKI
- P-114 Significance of hepatic progenitor cell marker-positive hepatocellular carcinoma and its possible prediction by AFP-L3**  
Atsunori TSUCHIYA, Yuichi KOJIMA, Satoshi SEINO, Yusuke WATANABE, Yuzo KAWADA, Shunzo IKARASHI, Suguru TAKEUCHI, Toru SETSU, Akira SAKAMAKI, Satoshi ABE, Kenya KAMIMURA, Masaaki TAKAMURA, Kawai HIROKAZU, Satoshi YAMAGIWA, Shuji TERAI
- P-115 Recent trend in real-world anti-viral treatment options for genotype 1b chronic hepatitis C in Japan**  
Kenichi IKEJIMA, Kyoko FUKUHARA, Tomonori AOYAMA, Akira UCHIYAMA, Kazuyoshi KON, Shunhei YAMASHINA, Sumio WATANABE
- P-116 Combination therapy with Daclatasvir and asunaprevir for the patients infected with HCV genotype 1**  
Masakuni TATEYAMA, Motohiko TANAKA, Takehisa WATANABE, Hiroko SETOYAMA, Takeyasu KOUNOE, Yoshinari SAKAI, Masato SASAKI, Kazuhiro SUGI, Shiho MIYASE, Shigetoshi FUJIYAMA, Yutaka SASAKI
- P-117 Ledipasvir/Sofosbuvir decreases risk factors associated with hepatocellular carcinoma in patients with chronic hepatitis C**  
Masaaki KORENAGA, Keiko KORENAGA, Tatsuya KANTO, Masashi MIZOKAMI
- P-118 Clinical outcomes of patients with hepatitis C virus-related hepatocellular carcinoma obtaining viral eradication after interferon therapy**  
Motohiko TANAKA, Yoko YOSHIMARU, Takayuki TOKUNAGA, Takeshi KAWASAKI, Satomi FUJIE, Takayoshi SONODA, Takehisa WATANABE, Hiroko SETOYAMA, Masakuni TATEYAMA, Yutaka SASAKI

- P-119**      **Activation of protein kinase R by hepatitis C virus RNA-dependent RNA polymerase**  
 Ryosuke SUZUKI, Mami MATSUDA, Takashi SHIMOIKE, Koichi WATASHI, Hideki AIZAKI, Takanobu KATO, Tetsuro SUZUKI, Takaji WAKITA
- P-120**      **Immunotherapeutic effects and altered cell metabolism by the newly identified agent targeting the GWAS-discovered susceptibility gene for HCV-HCC**  
 Kaku GOTO, Wenwen LI, Sayaka ITO, Jun ARAI, Anthony STEPHANOU, Ryosuke MUROYAMA, Yasuo MATSUBARA, Ryo NAKAGAWA, Yasushi TANOUE, Sayuri MORIMOTO, Yoshimi KAISE, Lay LIM, Masahisa JINUSHI, Naoya KATO
- P-121**      **IFN-  $\lambda$  4 potently blocks IFN-  $\alpha$  signaling by ISG15 and USP18 in HCV infection**  
 Eui-Cheol SHIN, Pil Soo SUNG, Hong SEON-HUI, Park SU-HYUNG
- P-122**      **Hepatitis C virus is targeted by natural killer cells through the induction of NKG2D ligand in human non-neoplastic hepatocyte cells**  
 Hiromichi DANSAKO, Hiroki HIRAMOTO, Youki UEDA, Shinya SATOH, Nobuyuki KATO
- P-123**      **Cleavage of MAVS and interference with innate-immune signaling is conserved among hepaciviral NS3/4A proteases**  
 Thomas PIETSCHMANN, Angga KUSUMA, Richard JP BROWN, Dominic H BANDA, Gabrielle VIEYRES, Michael ENGELMANN, Eike STEINMANN
- P-124**      **Selenoprotein P, a liver-derived secretory protein, regulates RIG-I-mediated innate immunity in hepatocytes**  
 Kazuhisa MURAI, Masao HONDA, Tetsuro SHIMAKAMI, Takayoshi SHIRASAKI, Hirofumi MISU, Toshinari TAKAMURA, Stanley M LEMON, Seishi MURAKAMI, Shuichi KANEKO
- P-125**      **Tumor Necrosis Factor-  $\alpha$  inhibits HCV spread independently of interferons**  
 Stephen M LAIDLAW, Svetlana MARUKIAN, Rachel GILMORE, Siobhán B CASHMAN, Charles M RICE, Lynn b DUSTIN
- P-126**      **Hepatitis C Virus Nonstructural 5A Inhibits Type I IFN-  $\beta$  -induced Antiviral Immunity by Targeting the IKK  $\epsilon$  /DDX3 Complex**  
 Byeong-Sun CHOI, Sang-Min KANG, Ji-Young PARK, Ju-Yeon CHOI, Chun KANG
- P-127**      **Long non-coding RNA #32 confers to antiviral responses by controlling interferon-stimulated gene expression**  
 Hironori NISHITSUJI, Saneyuki UJINO, Kunitada SHIMOTOHNO
- P-128**      **Hepatitis C virus replicative double-stranded RNA is a potent interferon inducer that triggers interferon production through MDA5**  
 Zhigang YI, Xiaoting DU, Zhenghong YUAN
- P-129**      **Activity-based protein profiling of the role of 25-hydroxycholesterol and miRNA-185 in the immunometabolic response to Hepatitis C infection**  
 Roxana FILIP, Genevieve DESROCHERS, John P PEZACKI

**P-130**

**Two different roles of ISG15 in HCV infection**

Ikuo SHOJI, Nanae MINAMI, Chieko MATSUI, Tutik Sri WAHYUNI, Lin DENG

**P-131**

**Monocytes-derived Galectin-9 activates NK cells in chronic hepatitis C**

Tomohide TATSUMI, Akira NISHIO, Takahiro SUDA, Tadashi KEGASAWA, Seiichi TAWARA, Teppei YOSHIOKA, Satoshi AONO, Minoru SHIGEKAWA, Hayato HIKITA, Ryotaro SAKAMORI, Tetsuo TAKEHARA

- P-132**      **Comprehensive Analysis of Human Hepatitis C Virus Specific T Cell Responses in the Presence or Absence of Direct-acting Antiviral Therapy**  
Chao ZHANG, Rui HUA, Yuanyuan CUI, Shasha WANG, Yonghong ZHANG, Zhengkun TU, Pei HAO, Xinyue CHEN, Jin ZHONG, Junqi NIU, Xia JIN
- P-133**      **A TCF1<sup>+</sup> memory-like population of HCV-specific CD8<sup>+</sup> T-cells is maintained after DAA-mediated antigen withdrawal**  
Dominik WIELAND, Anita SCHUCH, Janine KEMMING, Dietmar ZEHN, Werner HELD, Christoph NEUMANN-HAEFELIN, Maike HOFMANN, Robert THIMME
- P-134**      **Immunogenicity of highly conserved E2 epitope of HCV exposed on the surface of Leishmania-derived hepatitis B small antigen particles**  
Anna CZARNOTA, Jolanta TYBOROWSKA, Grażyna PESZYŃSKA-SULARZ, Beata GROMADZKA, Krystyna BIENKOWSKA-SZEWCZYK, Katarzyna GRZYB
- P-135**      **Low quasispecies diversity: a new risk factor associated with vertical transmission of hepatitis C virus**  
Ariane LAROUCHE, Armelle LE CAMPION, Virginie CALDERON, Sébastien FAUTEUX-DANIEL, Kimberly Ann MILTON MCSWEEN, Marc BOUCHER, Normand LAPOINTE, Mel KRAJDEN, Deborah M. MONEY, Hugo SOUDEYNS
- P-136**      **Reversal of peripheral and intrahepatic HCV-specific CD8<sup>+</sup> T cell exhaustion after removal of cognate antigen**  
Pierre TONNERRE, Jihad AL-JABBAN, Damien TULLY, David BEAN, Joelle BROWN, David WOLSKI, Almudena TORRES-CORNEJO, Maxwell ROBIDOUX, Daniel KVISTAD, Jenna GUSTAFSON, Jasneet ANEJA, Todd ALLEN, Raymond T CHUNG, Arthur Y KIM, Georg M LAUER
- P-137**      **Multiple flaviviruses neutralization assay based on single-round infectious particles**  
Mami MATSUDA, Atsushi YAMANAKA, Kentaro YOSHII, Koichi WATASHI, Hideki AIZAKI, Eiji KONISHI, Tomohiko TAKASAKI, Takaji WAKITA, Ryosuke SUZUKI
- P-138**      **Commitment to CD8<sup>+</sup> T cell exhaustion and loss of memory T cell potential develops during primary chronic HCV infection**  
Mehdi RASOLI PIROZYAN, Preston LEUNG, Auda ELTAHLA, Simone RIZZETTO, Oanh NGUYEN, Katherine KEDZIERSKA, Andrew LLOYD, Rowena BULL, Fabio LUCIANI
- P-139**      **Deep sequencing and functional analysis of HCV broadly neutralizing antibody AR3C**  
Erick GIANGLI, Linling HE, Jiang ZHU, Mansun LAW
- P-140**      **CpG oligonucleotides complexed with dectin-1 ligand enhances humoral and cellular immune response to HBV vaccine**  
Hiroyasu ITO, Motohiro NAKAMURA, Hidekazu ISHIDA, Kouji KOBAYAMA, Takuya YAMAMOTO, Ken J. ISHII, Mitsuru SEISHIMA, Tetsuya ISHIKAWA
- P-141**      **Global Mapping of Antibody Recognition of the Hepatitis C Virus E2 Glycoprotein: Implications for Vaccine Design**  
Brian G. PIERCE, Zhen-yong KECK, Catherine FAUVELLE, Ragul GOWTHAMAN, Thomas R FUERST, Roy A MARIUZZA, Thomas F BAUMERT, Steven KH FOUNG



- P-142**      **Functional homology of hepacivirus 5' UTRs in IRES activity and replication**  
Tomohisa TANAKA, Teruhime OTOGURO, Atsuya YAMASHITA, Hirotake KASAI, Kohji MORIISHI
- P-143**      **Comparative study of in vivo evolution of hepaciviral glycoproteins in humans and horses**  
Thomas PIETSCHMANN, Daniel TODT, Richard JP BROWN, Stephanie WALTER, Juliane DOERRBECKER, Stephanie PFAENDER, Heiner WEDEMEYER, Eike STEINMANN
- P-144**      **Innate Antiviral Immune Responses to Hepatitis Viruses in *Tupaia belangeri***  
Mohammad E. H. KAYESH, Sayeh EZZIKOURI, Haiying CHI, Takahiro SANADA, Naoki YAMAMOTO, Bouchra KITAB, Aya MATSUU, Hitoshi HATAI, Noriaki MIYOSHI, Michinori KOHARA, Kyoko TSUKIYAMA-KOHARA
- P-145**      **The Role of Hepatitis C Virus Capsid Protein in the Preservation and Nuclear Translocation of Phospho-IkBalpa**  
Wesley WILLIAMS, Julia WEISBROD, Tracy BUSHUR, Steven ZAMORA, Roland WOLKOWICZ
- P-146**      **Both selection from quasispecies and new mutation during treatment are involved in emerging resistance-associated substitution of HCV after DAA treatment**  
Hayato HIKITA, Yugo KAI, Tomohide TATSUMI, Naoki MORISHITA, Ryoko YAMADA, Takayuki YAKUSHIJIN, Yasuteru KONDO, Takanobu KATO, Hiroshi SUJEMIZU, Ryotaro SAKAMORI, Tetsuo TAKEHARA
- P-147**      **Examination as the hepatocytes carcinogenesis model of the PLC/PRF/5 cell strain**  
Tomohiro KANEKO, Shouichi SASAKI, Tomotaka ISHII, Katsutoshi SHIBATA, Mitsuhiro MORIYAMA

- P-148** **Novel Anti-Hepatitis C Virus Activity of *Spatholobus Suberectus***  
Ying WANG, Shao-Ru CHEN, An-Qi WANG, Li-Gen LIN, Yi-Tao WANG
- P-149** **Evaluation of Antiviral Activities of Vitamin D Derivatives in Hepatitis C Virus Lifecycle**  
Asako MURAYAMA, Nao SUGIYAMA, Takaji WAKITA, Takanobu KATO
- P-150** **Identification and characterization of human monoclonal anti-HCV antibodies cloned from chronic hepatitis C patients**  
Hiroshi YOKOKAWA, Midori SHINOHARA, Noriko NAKAMURA, Tomokatsu IWAMURA, Tomohiko SUZUKI, Takaji WAKITA
- P-151** **Mitochondria F1-F0 ATP synthase facilitates dengue virus replication and serves as a potential target for developing antiviral agents**  
Chin-Kai TSENG, Chun-Kuang LIN, Yu-Hsuan WU, Kung-Chia YOUNG, Jin-Ching LEE
- P-152** **Anti-hepatitis C virus compounds from *Ruta angustifolia* mediate a synergistic effect in combination with current direct-acting antiviral agents**  
Tutik Sri WAHYUNI, Aty WIDYAWARUYANTI, Maria Inge LUSIDA, Achmad FUAD, Lin DENG, Chieko MATSUI, Hiroyuki FUCHINO, Nobuo KAWAHARA, Ikuo SHOJI, Hak HOTTA
- P-153** **USP18 interacts with HCV core protein to inhibit the core-induced activation of Jak/STAT signaling pathway: implications for viral persistence**  
Xuezhen SHI, Shilin LI, Limin CHEN
- P-154** **Antiviral activities of the scorpine-like peptide Smp76 isolated from *Scorpio maurus palmatus* against dengue virus and hepatitis C virus**  
Hak HOTTA, Alaa A. EL-BITAR, Moustafa M. SARHAN, Mohamed A. RAHMAN, Lourival D. POSSANI, Ming CHEN, Lin DENG, Chie A. UTSUBO
- P-155** **Natural product LH extracted from Formosan soft coral suppresses hepatitis C virus replication through reducing the MAPK-JNK/c-Jun-C/EBP-regulated cyclooxygenase-2 expression**  
Wei Han CHEN, Chun-Kuang LIN, Chin-Kai TSENG, Yu-Hsuan WU, Chih-Chuang LIAW, Jin-Ching LEE
- P-156** **Targeted Screening for Anti- Hepatitis C Virus Compounds via Ultra High-Throughput Screening**  
Jun-Wei LEE, Luh TUNG, Tien-Hsien CHANG
- P-157** **Development of tools to investigate resistance of hepatitis C virus genotype 3 to direct acting inhibitors of nonstructural protein 5A**  
Lorna J KELLY, Jack SILBERRAD, Anjna BADHAN, Jean Lutamyo MBISA, Mark HARRIS
- P-158** **Cultivated cell-based evaluation of apolipoproteins with the treatment of direct-acting antiviral agents against hepatitis C virus infection**  
Chen Wei TSAI, Yu Hung SUN, Ying Chiung TSENG, Nan Pin CHENG, Cheng Yen CHIU, Tsung Ting CHANG, Chia Kung YOUNG

- P-159**      **Celastrol inhibits hepatitis C virus activity by inducing heme oxygenase-1 through the nuclear factor erythroid 2-related factor 2 pathway**  
Hsing-Ju WU, Li-Chuan LIN, Jin-Ching LEE
- P-160**      **Towards a scalable HCV vaccine: Purification and immunogenicity of a functional gpE1/gpE2 heterodimer isolated from an Fc domain tagged precursor**  
Michael R LOGAN, John LAW, Jason Alexander Ji-Xhin WONG, Darren HOCKMAN, Amir LANDI, Chao CHEN, Kevin CRAWFORD, Juthika KUNDU, Lesley BALDWIN, Janelle JOHNSON, Anita DAHIYA, Gerald LACHANCE, Lorne TYRRELL, Michael HOUGHTON
- P-161**      **Signal peptide peptidase as a target for anti-HCV drug**  
Toru OKAMOTO, Junki HIRANO, Tatsuya SUZUKI, Shinji KUSAKABE, Takasuke FUKUHARA, Kohji MORIISHI, Kazuhiko KOIKE, Yoshiharu MATSUURA
- P-162**      **Role of lipid droplets in the emergence of drug resistant virus against direct acting antivirals**  
Hirofumi OHASHI, Syo NAKAJIMA, Sulyi KIM, Ryosuke SUZUKI, Hideki AIZAKI, Masayoshi FUKASAWA, Shinji KAMISUKI, Fumio SUGAWARA, Naoko OHTANI, Takaji WAKITA, Koichi WATASHI
- P-163**      **Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor as one option for anti-hepatitis C treatment**  
Hikari HASEGAWA, Yasunori NIO, Hitomi OKAMURA, Yohei MIYAYAMA, Yuichi AKAHORI, Makoto HIJIKATA
- P-164**      **Synergistic Inhibition of HCV Replication by Combination of a PRK2 Inhibitor and Direct-acting Antivirals**  
Bo-Yeong PAK, Jae-Su MOON, Seung-Hoon LEE, Jong-Won OH
- P-165**      **Immunization with cocktails of chimeric HBV-HCV particles bearing HCV envelopes from different genotypes elicits broadly cross-neutralizing antibody responses**  
Elodie E.B. BEAUMONT, Clement B.C. BENOIT, Guerin V.G. VANESSA, Chopin L.C. LUCIE, Roingeard P.R. PHILIPPE
- P-166**      **Broadly active antivirals with a naturally derived chelating moiety targeting hepaci- and flavivirus replication; further evaluation under liver normoxic conditions**  
Efseveia FRAKOLAKI, Erofilis GIANNAKOPOULOU, Vassilios MYRIANTHOPOULOS, Marios DIMITRIOU, Vanessa MADAN, Emmanouel MIKROS, Ralf BARTENSCHLAGER, Penelope MAVROMARA, Grigoris ZOIDIS, Niki VASSILAKI
- P-167**      **Protease inhibitor-, concentration- and genotype-dependent distribution of NS3 resistance substitutions in HCV genotype 1-6 populations treated with grazoprevir and paritaprevir**  
Sanne B. JENSEN, Ulrik FAHNOE, Qi TANG, Lubna GHANEM, Santseharay RAMIREZ, Daryl HUMES, Long VAN PHAM, Stephanie SERRE, Jens BUKH, Judith GOTTWEIN

- P-168**      **The Discovery and Development of an Aryloxazole Class of Compounds as a Hepatitis C Virus Entry Inhibitor**  
Zongyi HU, He SHANSHAN, Derek LE, Kelin LI, Xin HU, Amy WANG, Marc FERRER, Noel SOUTHALL, Jeffrey AUBÉ, Frank J SCHOENEN, Kazuaki CHAYAMA, Juan J MARUGAN, Kevin J FRANKOWSKI, T. Jake LIANG
- P-169**      **Guanfacine inhibits hepatitis C virus RNA replication**  
Midori TAKEDA, Nobuyuki KATO, Masanori IKEDA
- P-170**      **ACRIDONE FAC4 EFFICIENTLY INHIBITS IN VITRO REPLICATION OF HEPATITIS C VIRUS**  
Paula RAHAL, Campos R. F. GUILHERME, Ana Carolina G. JARDIM, Jacqueline F. SHIMIZU, Mariana N. BATISTA, Eder R. PAGANINI, Mark HARRIS, Luis O. REGASINI, Cintia BITTAR
- P-171**      **HECATE AND ITS N-TERMINUS DERIVATIVES INHIBIT ENTIRE HCV REPLICATION CYCLE NON-GENOTYPE SPECIFIC**  
Paula RAHAL, Mariana Nogueira BATISTA, Paulo Ricardo da Silva SANCHES, Ana Cláudia Silva BRAGA, Guilherme Rodrigues Fernandes CAMPOS, Eduardo Maffudi CILLI, Bruno Moreira CARNEIRO
- P-172**      **Optimum cellular and humoral immune responses elicited by a hepatitis C virus E1E2 vaccine adjuvanted with cyclic-di-adenosine monophosphate and archaosomes**  
Abdolamir LANDI, John LAW, Darren HOCKMAN, Michael LOGAN, Kevin CRAWFORD, Chao CHEN, Juthika KUNDU, Carlos A. GUZMAN, Lise DESCHATELETS, Lakshmi KRISHNA, Lorne TYRRELL, Michael HOUGHTON
- P-173**      **Development of anti-HCV drug candidates targeting NS5A**  
Md Shafiqur RAHMAN, Hee Sun KIM, Il Hak BAE, Youngsu YOU, Byung Moon KIM, Michinori KOHARA, Sung Key JANG
- P-174**      **Properties of neutralizing antibodies elicited by a HCV vaccine candidate**  
Jason A WONG, Michael LOGAN, Darren HOCKMAN, Rakesh BHAT, Chao CHEN, Aviad LEVIN, Abdul KHAN, Jillian WHITBY, Joseph MARCOTRIGIANO, Sharon FREY, Robert BELSHE, D. Lorne TYRRELL, John LAW, Michael HOUGHTON
- P-175**      **Development of Novel Anti-viral Agents against Hepatitis B Virus by using an siRNA Screening Panel Targeting the Carbohydrate Synthesis System**  
Kiyooki ITO, Masashi YONEDA, Kiyohiko ANGATA, Koichi WATASHI, Takaji WAKITA, Yasuhito TANAKA, Masashi MIZOKAMI, Hisashi NARIMATSU
- P-176**      **Conjugation of HCV E2 envelope protein with ferritin forms a nanoparticle vaccine with improved antigenicity that efficiently induces neutralizing antibodies**  
Xuesong WANG, Yu YAN, Dapeng LI, Jin ZHONG, Zhong HUANG

- P-177**      **Establishment of the method for evaluating molecular interaction between hepatitis B virus entry inhibitors and sodium taurocholate cotransporting polypeptide**  
Kento FUKANO, Satomi SHIMURA, Michael PEEL, Ann SLUDER, Fumihiko KAWAI, Senko TSUKUDA, Ryosuke SUZUKI, Hideki AIZAKI, Sam-Yong PARK, Takaji WAKITA, Yuki OGASAWARA, Koichi WATASHI
- P-178**      **Population Pharmacokinetic Analysis of Ledipasvir/Sofosbuvir in Japanese Subjects with Chronic Genotype 1 HCV Infection**  
Yoshiyuki UENO, Kimberly L GARRISON, Bing GAO, Phil PANG, Steven KNOX, Anita MATHIAS
- P-179**      **Endoplasmic Reticulum Stress Links Hepatitis C Virus RNA Replication to Wild-Type PGC-1  $\alpha$  /Liver-Specific PGC-1  $\alpha$  Upregulation**  
Wenxia YAO, Hua CAI, Xinlei LI, Ting LI, Longbo HU, Tao PENG